These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 24604591)
21. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. Fung EK; Cheal SM; Fareedy SB; Punzalan B; Beylergil V; Amir J; Chalasani S; Weber WA; Spratt DE; Veach DR; Bander NH; Larson SM; Zanzonico PB; Osborne JR EJNMMI Res; 2016 Dec; 6(1):7. PubMed ID: 26801327 [TBL] [Abstract][Full Text] [Related]
22. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Petrul HM; Schatz CA; Kopitz CC; Adnane L; McCabe TJ; Trail P; Ha S; Chang YS; Voznesensky A; Ranges G; Tamburini PP Mol Cancer Ther; 2012 Feb; 11(2):340-9. PubMed ID: 22147747 [TBL] [Abstract][Full Text] [Related]
23. ImmunoPET of Malignant and Normal B Cells with Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164 [No Abstract] [Full Text] [Related]
27. Imaging of carbonic anhydrase IX with an 111In-labeled dual-motif inhibitor. Yang X; Minn I; Rowe SP; Banerjee SR; Gorin MA; Brummet M; Lee HS; Koo SM; Sysa-Shah P; Mease RC; Nimmagadda S; Allaf ME; Pomper MG Oncotarget; 2015 Oct; 6(32):33733-42. PubMed ID: 26418876 [TBL] [Abstract][Full Text] [Related]
28. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350 [TBL] [Abstract][Full Text] [Related]
29. [Expression of carbonic anhydrase IX, PAX2 and PAX8 and their association with clinicopathologic characteristics in renal epithelial tumors]. Zhang W; Yu WJ; Xia Y; Liu Y; Liu XL; Zhuang J; Li YJ Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):442-5. PubMed ID: 24246861 [TBL] [Abstract][Full Text] [Related]
30. Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. Bauer S; Oosterwijk-Wakka JC; Adrian N; Oosterwijk E; Fischer E; Wüest T; Stenner F; Perani A; Cohen L; Knuth A; Divgi C; Jäger D; Scott AM; Ritter G; Old LJ; Renner C Int J Cancer; 2009 Jul; 125(1):115-23. PubMed ID: 19384924 [TBL] [Abstract][Full Text] [Related]
31. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Davis ID; Wiseman GA; Lee FT; Gansen DN; Hopkins W; Papenfuss AT; Liu Z; Moynihan TJ; Croghan GA; Adjei AA; Hoffman EW; Ingle JN; Old LJ; Scott AM Cancer Immun; 2007 Aug; 7():13. PubMed ID: 17705349 [TBL] [Abstract][Full Text] [Related]
33. Novel VHH-Based Tracers with Variable Plasma Half-Lives for Imaging of CAIX-Expressing Hypoxic Tumor Cells. van Lith SAM; Huizing FJ; Franssen GM; Hoeben BAW; Lok J; Doulkeridou S; Boerman OC; Gotthardt M; van Bergen En Henegouwen PMP; Bussink J; Heskamp S Mol Pharm; 2022 Oct; 19(10):3511-3520. PubMed ID: 35044182 [TBL] [Abstract][Full Text] [Related]
34. Binding of the phage display derived peptide CaIX-P1 on human colorectal carcinoma cells correlates with the expression of carbonic anhydrase IX. Askoxylakis V; Ehemann V; Rana S; Krämer S; Rahbari NN; Debus J; Haberkorn U Int J Mol Sci; 2012 Oct; 13(10):13030-48. PubMed ID: 23202936 [TBL] [Abstract][Full Text] [Related]
35. Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. Pan J; Lau J; Mesak F; Hundal N; Pourghiasian M; Liu Z; Bénard F; Dedhar S; Supuran CT; Lin KS J Enzyme Inhib Med Chem; 2014 Apr; 29(2):249-55. PubMed ID: 23463940 [TBL] [Abstract][Full Text] [Related]
36. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. Xu C; Lo A; Yammanuru A; Tallarico AS; Brady K; Murakami A; Barteneva N; Zhu Q; Marasco WA PLoS One; 2010 Mar; 5(3):e9625. PubMed ID: 20224781 [TBL] [Abstract][Full Text] [Related]
37. Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. Hendrickx BW; Punt CJ; Boerman OC; Postema EJ; Oosterwijk E; Mavridu A; Corstens FH; Oyen WJ Cancer Biother Radiopharm; 2006 Jun; 21(3):263-8. PubMed ID: 16918303 [TBL] [Abstract][Full Text] [Related]